 |
|
Lymphoma Rates Are Low but Increased in Patients With Psoriasis
Results From a Population-Based Cohort Study in the United Kingdom
Joel M. Gelfand, MD, MSCE;
Jesse Berlin, ScD;
Abby Van Voorhees, MD;
David J. Margolis, MD, PhD
Arch Dermatol. 2003;139:1425-1429.
Objective To determine if the rate of lymphoma in patients with a history of psoriasis is different from the rate of lymphoma in patients without psoriasis.
Design Cohort study.
Setting Outpatient practices of general practitioners in the United Kingdom who contribute to the General Practice Research Database.
Patients The population studied was a sample of 10% of the patients 65 years or older registered with a general practitioner contributing to the General Practice Research Database between 1988 and 1996.
Main Outcome Measure The rate of lymphoma in patients with psoriasis compared with the rate of lymphoma in patients without psoriasis.
Results There were 2718 patients who had psoriasis and 105 203 patients (the reference population) who did not have psoriasis. The median follow-up time was 46 months. We noted 276 lymphomas. Patients with psoriasis had a 2.95 relative rate of developing lymphoma (95% confidence interval, 1.83-4.76) compared with those without psoriasis. This estimate did not change after controlling for age and sex using the Cox multivariable proportional hazards model. The rate of lymphoma changed little when the patients treated with methotrexate or those who developed mycosis fungoides were excluded. Compared with the reference population, we found an additional 122 lymphomas per 100 000 patients annually among patients with psoriasis who were 65 years or older.
Conclusions These results indicate that patients with psoriasis are at increased risk for developing lymphoma. Additional studies are necessary to determine if the increased rate of lymphoma is related to psoriasis severity, psoriasis treatment, or an interaction between these risk factors.
From the Department of Dermatology (Drs Gelfand, Van Voorhees, and Margolis) and the Center for Clinical Epidemiology and Biostatistics (Drs Gelfand, Berlin, and Margolis), University of Pennsylvania, Philadephia. Dr Margolis has consulted for Novartis, Biogen, GlaxoSmithKline, and Amgen; Dr Van Voorhees has consulted for or received grants from Amgen, Boehringer, and IDEC Pharmaceuticals.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Risk of Mortality in Patients With Psoriasis: Results From a Population-Based Study
Gelfand et al.
Arch Dermatol 2007;143:1493-1499.
ABSTRACT
| FULL TEXT
Incidence and Risk Factors for Psoriasis in the General Population
Huerta et al.
Arch Dermatol 2007;143:1559-1565.
ABSTRACT
| FULL TEXT
Psoriasis: advances in pathophysiology and management
MacDonald and Burden
Postgrad. Med. J. 2007;83:690-697.
ABSTRACT
| FULL TEXT
Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.
Smedby et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:2069-2077.
ABSTRACT
| FULL TEXT
Risk of myocardial infarction in patients with psoriasis.
Gelfand et al.
JAMA 2006;296:1735-1741.
ABSTRACT
| FULL TEXT
Lymphoma Risk in Psoriasis: Results of the PUVA Follow-up Study.
Stern
Arch Dermatol 2006;142:1132-1135.
ABSTRACT
| FULL TEXT
Psoriasis and its management
Smith and Barker
BMJ 2006;333:380-384.
FULL TEXT
Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
Smedby et al.
JNCI J Natl Cancer Inst 2006;98:51-60.
ABSTRACT
| FULL TEXT
Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study
Gelfand et al.
Arch Dermatol 2005;141:1537-1541.
ABSTRACT
| FULL TEXT
Patients with Psoriasis Have a Slightly Increased Risk for Lymphoma
Journal Watch Dermatology 2003;2003:2-2.
FULL TEXT
|
